Psoriasis: Is ustekinumab superior to etanercept for psoriasis?
Kuhn
Annegret
A
Department of Dermatology, University of Muenster, Von-Esmarch-Strasse 58, D-48149 Muenster, Germany. kuhnan@uni-muenster.de
Luger
Thomas A
TA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017326:Clinical Trials, Phase III as Topic; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069549:Ustekinumab; D000068800:Etanercept
Lancet. 2009 Feb 21;373(9664):633-40
19217154
J Immunol. 2005 Aug 15;175(4):2721-9
16081850
Trends Immunol. 2006 Jan;27(1):17-23
16290228
N Engl J Med. 2010 Jan 14;362(2):118-28
20071701
Lancet. 2008 May 17;371(9625):1675-84
18486740
Nat Rev Drug Discov. 2008 Nov;7(11):880-1
18974743
Lancet. 2008 May 17;371(9625):1665-74
18486739
N Engl J Med. 2005 May 5;352(18):1899-912
15872205
Nat Biotechnol. 2008 Dec;26(12):1317-8
19060851
J Exp Med. 2007 Dec 24;204(13):3183-94
18039949